

1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Isaac Jesus Rondon and Robert Charles Ladner

Application No.: 09/825,517

Group Art Unit: 1642

Filed: April 3, 2001

Examiner: Ungar, S.

Confirmation No.: 2019

Title: BINDING PEPTIDES FOR CARCINOEMBRYONIC ANTIGEN (CEA)

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
Date 10-07-03	Signature Dawn M Myers
Typed or printed name of person signing certificate DAWN M MYERS	

RECEIVED  
OCT 14 2003  
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

RECEIVED  
OCT 14 2003  
FBI CENTER 1600/1800

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.


Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references (AH, AE2-AH2, AE3-AH3, AE4-AH4, AE5, AS-AZ, and AI2-AV2) are enclosed.
- ☐ Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
- ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☒ The listed references were cited in the enclosed European Search Report in a counterpart foreign application.
- ☒ The "concise explanation" requirement (non-English references) for references AF3, AG4, and AH4 under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed European Search Report.
- ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
- ☒ the enclosed English language abstract.

REMARKS

Please note that portion of pages 368 and 384 of WO 01/75068 are cut-off and page 101 of WO 01/57274 is missing. These published PCT applications are published in this manner by the World Intellectual Property Organization.



Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_  
Examiner

\_\_\_\_\_  
Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Lisa M. Treannie

Lisa M. Treannie

Registration No.: 41,368

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: 10/7/03

RECEIVED  
OCT 14 2003  
TECH CENTER 160012900

APPLICATION NO.  
09/825,517

Isaac Jesus Rondon and Robert Charles Ladner

FILING DATE  
April 3, 2001

CONFIRMATION NO.  
2019

GROUP  
1642

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

**October 1, 2003**

(Use several sheets if necessary)

## FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3421.1005-001APPLICATION NO.  
09/825,517INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

APPLICANT

Isaac Jesus Rondon and Robert Charles Ladner

October 1, 2003

FILING DATE  
April 3, 2001CONFIRMATION NO.  
2019GROUP  
1642


(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AS	Aljinovic, G., and Pohl, T.M., "Sequence and Analysis of 24 kb on Chromosome II of <i>Saccharomyces cerevisiae</i> ," <i>Yeast</i> , 11(5):475-479 (1995).
AT	Amerik, A.Y., <i>et al.</i> , "In vivo Disassembly of Free Polyubiquitin Chains by Yeast Ubp14 Modulates Rates of Protein Degradation by the Proteasome," <i>EMBO J.</i> , 16(16):4826-4838 (1997).
AU	Brown, D.D., <i>et al.</i> , "The Thyroid Hormone-induced Tail Resorption Program During <i>Xenopus laevis</i> Metamorphosis," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 93(5):1924-1929 (1996).
AV	Cheret, G., <i>et al.</i> , "DNA Sequence Analysis of the <i>VPH1-SNF2</i> Region on Chromosome XV of <i>Saccharomyces cerevisiae</i> ," <i>Yeast</i> , 12:1059-1064 (1996).
AW	Duharcourt, S., <i>et al.</i> , "Homology-Dependent Maternal Inhibition of Developmental Excision of Internal Eliminated Sequences in <i>Paramecium tetraurelia</i> ," <i>Mol. Cell Biol.</i> , 18(12):7075-7085 (1998).
AX	Hennessy, S.W., <i>et al.</i> , "Complete Thrombospondin mRNA Sequence Includes Potential Regulatory in the 3' Untranslated Region," <i>J. Cell Biol.</i> , 108(2):729-736 (1989).
AY	Hiroto, K., <i>et al.</i> , "Molecular Cloning of Equine Interleukin-1 $\alpha$ and - $\beta$ cDNAs," <i>Vet. Immunol. Immunopathol.</i> , 48:221-231 (1995).
AZ	Huang, D., <i>et al.</i> , "Structural Organization and Splice Variants of the <i>POLE1</i> Gene Encoding the Catalytic Subunit of Human DNA Polymerase $\epsilon$ ," <i>Biochem. J.</i> , 339(3):657-665 (1999).
AI2	Huang, D., <i>et al.</i> , "cDNA and Structural Organization of the gene <i>Pole1</i> for the mouse DNA Polymerase $\epsilon$ Catalytic Subunit," <i>Biochim. Biophys. Acta</i> , 1445(3):363-371 (1999).
AJ2	Kato, H., <i>et al.</i> , "Identification of an Alternatively Spliced Transcript of Equine Interleukin-1 $\beta$ ," <i>Gene</i> , 177:11-16 (1996).

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED  October 1, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3421.1005-001	APPLICATION NO. 09/825,517	
	APPLICANT Isaac Jesus Rondon and Robert Charles Ladner		
	FILING DATE April 3, 2001	CONFIRMATION NO. 2019	GROUP 1642


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AK2	Kawano, T., <i>et al.</i> , "Structures of Insulin-like Peptides of the Nematode <i>Caenorhabditis elegans</i> ," <i>Peptide Science</i> , 35:117-120 (1998).
AL2	Kawano, T., <i>et al.</i> , "Molecular Cloning and Characterization of a New Insulin/IGF-like peptide of the Nematode <i>Caenorhabditis elegans</i> ," <i>Biochem. Biophys. Res. Commun.</i> , 273(2):431-436 (2000).
AM2	Kesti, T., <i>et al.</i> , "Molecular Cloning of the cDNA for the Catalytic Subunit of Human DNA Polymerase $\epsilon$ ," <i>J. Biol. Chem.</i> , 268(14):10238-10245 (1993).
AN2	Li, Y., <i>et al.</i> , "Purification, cDNA Cloning, and Gene Mapping of the Small Subunit of Human DNA Polymerase $\epsilon$ ," <i>J. Biol. Chem.</i> , 272(51):32337-32344 (1997).
AO2	Nielsen, E., <i>et al.</i> , "Cysteine Residue Periodicity is a Conserved Structural Feature of Variable Surface Proteins from <i>Paramecium tetraurelia</i> ," <i>J. Mol. Biol.</i> , 222(4):835-841 (1991).
AP2	Okinaka, R.T., <i>et al.</i> , "Sequence and Organization of pX01, the Large <i>Bacillus anthracis</i> Plasmid Harboring the Anthrax Toxin Genes," <i>J. Bacteriol.</i> , 181(20):6509-6515 (1999).
AQ2	Prat, A., "Conserved Sequences Flank Variable Tandem Repeats in two Alleles of the G Surface Protein of <i>Paramecium primaurelia</i> ," <i>J. Mol. Biol.</i> , 211(3):521-535 (1990).
AR2	Prat, A., <i>et al.</i> , "Nucleotide Sequence of the <i>Paramecium primaurelia</i> G Surface Protein," <i>J. Mol. Biol.</i> , 189(1):47-60 (1986).
AS2	Tachikawa, H., <i>et al.</i> , "Isolation and Characterization of a Yeast Gene, <i>MPD1</i> , the Overexpress of Which Suppresses Inviability Caused by Protein Disulfide Isomerase Depletion," <i>FEBS Lett.</i> , 369:212-216 (1995).
AT2	Thébault, S., <i>et al.</i> , "Molecular Cloning of a Novel Human I-mfa Domain-containing Protein That Differently Regulates Human T-cell Leukemia Virus Type I and HIV-1 Expression," <i>J. Biol. Chem.</i> , 275(7):4848-4857 (2000).

RECEIVED  
OCT 14 2003  
TECH CENTER 1600-4300

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED  October 1, 2003 (use several sheets if necessary)	ATTORNEY DOCKET NO. 3421.1005-001	APPLICATION NO. 09/825,517	
	APPLICANT Isaac Jesus Rondon and Robert Charles Ladner		
	FILING DATE April 3, 2001	CONFIRMATION NO. 2019	GROUP 1642

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AU2	Ueno, A., <i>et al.</i> , "cDNA Cloning of Bovine Thrombospondin 1 and its Expression in Odontoblasts and Predentin," <i>Biochim. Biophys. Acta</i> , 1382(1):17-22 (1998).
	AV2	Wang, H., <i>et al.</i> , "Genetic Diversity of Hantaviruses Isolated in China and Characterization of Novel Hantaviruses Isolated from <i>Niviventer confucianus</i> and <i>Rattus rattus</i> ," <i>Virology</i> , 278(2):332-345 (2000).

RECEIVED  
 OCT 14 2003  
 TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
----------	-----------------